搜索
 > 【EMMPRIN】重组蛋白信息

EMMPRIN信息

英文名称:Basigin
中文名称:Basigin蛋白
靶点别称:Extracellular matrix metalloproteinase inducer,CD_antigen=CD147,TCSF,EMMPRIN,BSG,Leukocyte activation antigen M6,5F7,Tumor cell-derived collagenase stimulatory factor,OK blood group antigen,Collagenase stimulatory factor,Basigin
上市药物数量:1
临床药物数量:2
最高研发阶段:批准上市

EMMPRIN产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
CD7-H5222
Human
Recombinant Human EMMPRIN / CD147 / Basigin Protein
CD7-H5259
Human
Recombinant Human EMMPRIN / CD147 / Basigin Protein
CD7-H82E0
Human
Biotinylated Human EMMPRIN / CD147 Protein, Avi Tag

EMMPRIN 分子别名

Basigin,BSG,5F7,CD147,EMMPRIN,M6,OK,TCSF

EMMPRIN 分子背景

CD147, also known as Basigin (BSG), or extracellular matrix metalloproteinase inducer (EMMPRIN). The human basigin protein contains 269 amino acids that form two heavily glycosylated C2 type immunoglobulin-like domains at the N-terminal extracellular portion. A second form of basigin has also been characterized that contains one additional immunoglobulin-like domain in its extracellular portion. As members of the immunoglobulin superfamily play fundamental roles in intercellular recognition involved in various immunologic phenomena, differentiation, and development, basigin is thought also to play a role in intercellular recognition and regulate several distinct functions, such as spermatogenesis, expression of the monocarboxylate transporter and the responsiveness of lymphocytes. Basigin is a type I integral membrane receptor that has many ligands, including the cyclophilin (CyP) proteins Cyp-A and CyP-B and certain integrins.

EMMPRIN 参考文献

EMMPRIN上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Iodine[131I] Metuximab 碘[131I]美妥昔单抗 批准上市 成都华神生物 Iodine[131I] Metuximab Injection cfda 肝细胞癌 2016-05-17 肝细胞癌 详情

EMMPRIN临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Gavilimomab CBL-1 临床三期 Abgenix, 健赞 银屑病, 移植物抗宿主病, 类风湿性关节炎, 肾移植排斥反应
Mertuzumab 临床一期 太平洋美诺克生物药业, 第四军医大学 非小细胞肺癌

消息提示

请输入您的联系方式,再点击提交!

确定